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Abstract
Pituitary apoplexy (PA) is a rare, potentially life-threatening medical condition due to acute ischaemia or haemorrhage of the pituitary gland. 
The main clinical features are: abrupt onset of severe headache, nausea, vomiting, deteriorating level of consciousness, visual impairment 
and/or endocrine deficiency. Correct and prompt diagnosis is essential for effective therapy, but there are no randomised studies or strict 
recommendations defining treatment modalities. We present the case of a 59 year-old woman with pituitary tumour apoplexy, presenting 
with severe headache, vomiting and visual field deterioration. The patient was treated conservatively because of her refusal of surgery and 
was followed-up for five years. In the course of treatment, recovery of the visual field defects, as well as right sixth cranial nerve paresis, 
was observed. Repeated magnetic resonance imaging (MRI) revealed regression of the tumour without signs of its re-growth. We discuss 
therapeutic modalities with particular emphasis on morbidity and review the literature relating to the management of pituitary tumour 
apoplexy. (Endokrynol Pol 2013; 64 (1): 54–58)
Key words: pituitary apoplexy, hypopituitarism, deep venous thrombosis, pituitary tumour, transsphenoidal surgery
Streszczenie
Udar przysadki jest rzadkim, potencjalnie zagrażającym życiu stanem spowodowanym martwicą niedokrwienną lub krwotoczną. Główne 
objawy kliniczne udaru przysadki to nagły, silny ból głowy, nudności, wymioty z towarzyszącym pogorszeniem stanu świadomości, za-
burzeniami widzenia i upośledzeniem czynności hormonalnej przysadki. Prawidłowe i szybkie rozpoznanie tego stanu ma podstawowe 
znaczenie dla wdrożenia właściwego leczenia. Dotychczas nie przeprowadzono badań randomizowanych oraz nie opracowano zaleceń 
wpływających na poprawę skuteczności leczenia udaru przysadki. Autorzy pracy opisują przypadek 59-letniej kobiety hospitalizowanej 
z powodu silnego bólu głowy, wymiotów i zaburzeń widzenia w przebiegu udaru przysadki. Chora nie wyrażała zgody na leczenie 
operacyjne i była leczona zachowawczo, a następnie poddana pięcioletniej obserwacji ambulatoryjnej. W trakcie hospitalizacji obser-
wowano poprawę pola widzenia oraz powrót prawidłowej czynności nerwu odwodzącego prawego. Kontrolne badanie MR przysadki 
wykazało regresję gruczolaka bez cech jego wznowy w czasie pięcioletniej obserwacji. Autorzy analizują różne metody leczenia udaru 
przysadki z uwzględnieniem ich następstw (powikłań) oraz prezentują na podstawie przeglądu piśmiennictwa wskazania terapeutyczne. 
(Endokrynol Pol 2013; 64 (1): 54–58)
Słowa kluczowe: udar przysadki, niedoczynność przysadki, żylna choroba zakrzepowo-zatorowa, guz przysadki, operacja przezklinowa
Introduction
Pituitary apoplexy (PA) is a rare, potentially life-
threatening medical condition caused by acute ischaemia 
or haemorrhage in the pituitary gland [1]. Percival Bailey 
first reported a massive, fatal haemorrhage to the pituitary 
tumour in 1898 [2]. Another case of a fatal haemorrhage 
in a somatotroph pituitary adenoma was described by 
Bleibtreu in 1905 [3]. In 1950, Brougham et al. presented 
the first comprehensive study of five patients and coined 
the term ‘pituitary apoplexy’ [1]. Over the past 30 years, 
several case reports and small series have emphasised the 
association of different predisposing factors with PA.
The main clinical features of PA are: abrupt onset of 
severe headache, nausea, vomiting, deteriorating level 
of consciousness, visual impairment and/or endocrine 
deficiency. Correct and prompt diagnosis is essential 
for effective therapy but there are no randomised stud-
ies or national recommendations defining treatment 
modalities.
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Case report
A 59 year-old, postmenopausal woman was admitted to 
the hospital following an episode of severe headache, 
nausea, vomiting and dizziness of around two weeks’ 
duration prior to admission. Additionally, the patient 
had experienced progressive visual impairment for 
the past six days. Six weeks prior to hospitalisation, 
deep vein thrombosis of the left lower extremity was 
diagnosed and a graded compression stocking and 
low molecular weight heparin (LMWH — Fraxiparine 
60 mg s.c. daily) was initiated. The patient was obese 
but without clinical symptoms of Cushing`s disease or 
acromegaly. The neurological and ophthalmological 
examination performed after admission to the Depart-
ment of Neurosurgery revealed a decrease of visual acu-
ity to 0.5 in both eyes, bilateral temporal field restriction, 
and diplopia. There was a limitation of abduction on the 
right side. The optic discs were normal in colour and 
shape. Apart from the visual impairment, neurological 
examination was normal. There were no signs of focal 
deficits, especially in terms of remaining cranial nerves. 
Vital signs and intracranial pressure was also normal. 
On the basis of full blood count and coagulation tests, 
clotting disturbances and heparin-induced thrombocy-
topenia (HIT) were excluded. Only the serum sodium 
level was slightly elevated to 148 mmol/L. Magnetic 
resonance imaging (MRI) revealed a pituitary tumour 
apoplexy (Fig. 1A, B, C).
In order to assess the pituitary function, hormone mea-
surements were performed and their results confirmed 
secondary adrenal insufficiency (Table I). The remaining 
hormone concentrations were within normal limits. 
There were no clinical signs of diabetes insipidus. Based 
on obtained results, pituitary tumour apoplexy with 
signs of secondary adrenal insufficiency was diagnosed. 
Treatment with hydrocortisone was initiated at a dose of 
200 mg i.v (t.i.d.), intravenous fluid replacement therapy 
and analgesia. The patient was treated conservatively 
because of lack of consent for surgical intervention. In 
the course of this treatment, the patient`s neurological 
state gradually and uneventfully improved. The visual 
abnormalities and right sixth cranial nerve paresis com-
pletely resolved. The patient was finally discharged on 
the 16th day of hospital stay on hydrocortisone replace-
ment therapy (at a dose of 30 mg/24 h).
The next hormone assessment performed three 
months later revealed multihormonal insufficiency of 
the anterior pituitary. Levothyroxine supplementation 
at a dose of 50 μg/24 h was initiated, and hydrocortisone 
replacement therapy was continued. MRI of the pitu-
itary performed three months later revealed no residual 
pituitary adenoma and a picture of secondary empty 
sella with slight displacement of the optic chiasm into 
the sella (Fig. 2A and B). The patient has been constantly 
followed-up in our outpatient clinic. In MRI repeated 
five years after the incidence of PA, there were no 
signs of tumour re-growth (Fig. 2 C and D). A complete 
insufficiency of the anterior lobe of the pituitary was 
confirmed, and continuous replacement therapy with 
hydrocortisone and levothyroxine was recommended 
at a dose of 30 mg/24 h and 100 μg, respectively.
Discussion
A correct diagnosis of PA can prove challenging. Mor-
tality and morbidity are predominantly caused by the 
delay in diagnosis and the lack of decision as to adequate 
therapy. The incidence of pituitary apoplexy is highly 
variable. Intratumoural haemorrhage and/or ischaemic 
infarction are not necessarily associated with clinical 
apoplectic events. Sometimes they might be a form of 
degeneration of the neoplasm [4]. Its incidence is esti-
mated at 9–15%. PA has been reported to occur with 
a frequency ranging from 0.6 to 30% [1]. It can occur at 
any age, with its peak in the fifth decade. Neither sex 
predominates.
The exact pathogenesis of PA is not completely 
understood. Biousse et al. identified four groups of so-
called precipitating conditions considered as triggering 
factors for PA [5]: 1) The reduced blood flow within the 
pituitary or the tumour, caused either by hypotension or 
transient increase of intracranial pressure; 2) An acute 
Figure 1. Gadolinium-enhanced T1-weighted sagittal and coronal 
MRI (A, B) and FLAIR sagittal (C) of the pituitary gland showing 
a 27 × 24 × 15 mm mass indicative of infarctive pituitary apoplexy 
with extension toward the right cavernous sinus and upward 
displacement of the optic chiasm. Enlargement of the sella turcica 
with typical thickening of the sphenoid sinus mucosa is visible
Rycina 1. Badanie MR, po podaniu środka kontrastowego 
w czasie T1-zależnym, w przekroju strzałkowym i czołowym (A, B) 
oraz przekroju strzałkowym w sekwencji FLAIR (C) uwidoczniło 
gruczolak przysadki o wymiarach 27 × 24 × 15 mm. Guz nacie ka 
prawą zatokę jamistą i uciska skrzyżowanie wzrokowe. Widoczne 
cechy udaru niedokrwiennego guza z towarzyszącym powiększeniem 
siodła tureckiego i charakterystycznym dla udaru pogrubieniem błony 
śluzowej zatoki klinowej
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increase in blood flow within the pituitary tumour; 
3) A hyperstimulation of the pituitary by oestrogen or 
due to dynamic testing (TRH, GnRH); and 4) Factors 
predisposing to anticoagulation (such as: haematologic 
diseases, anticoagulant therapy, thrombolytic agents).
It is commonly accepted that prompt and correct diag-
nosis of PA is essential in terms of further treatment and 
patient prognosis. The differential diagnosis includes: 
subarachnoid haemorrhage, aneurysmal rupture, 
infectious meningitis, temporal arteritis, migraine, 
intracerebral spontaneous haemorrhage, optic neuritis 
and cavernous sinus thrombosis [1].
LMWH is a widely accepted treatment of deep ve-
nous thrombosis [6]. However, such a treatment might 
lead to HIT which is the most feared complication of 
LMWH. It is characterised by a decrease in platelet count 
by 50% or to a number less than 100,000/mm3 occurring 
usually between the fifth and the 14th day of therapy [7].
In the presented case, standard anticoagulant 
therapy triggered a haemorrhage within a previously 
undiagnosed pituitary tumour. On the basis of com-
plete blood count, HIT was excluded. Simultaneously, 
administration of LMWH was continued because of the 
coexistence of serious risk factors of thromboembolic 
events (active deep venous thrombosis, prolonged im-
mobilisation, indwelling central venous catheter and 
prolonged hydrocortisone treatment).
Currently, MRI is considered to be more effective 
than computed tomography (CT) in detecting pituitary 
lesions and is the imaging method of choice for identify-
ing the features of PA [1, 8]. On MRI, PA may present as 
Table I. Hormonal test values measured on admission and after three months
Tabela I. Wyniki badań hormonalnych wykonane przy przyjęciu do szpitala oraz po 3 miesiącach od przebytego udaru guza 
przysadki
Measured value Reference range
                                                                 On admission                           After three months
GH 0.18 µg/L 0.13 µg/L < 5 µg/L
IGF-I 128 µg/L 69 µg/L 180–325 µg/L
ACTH – 13.2 pg/mL 10–60 pg/mL
Cortisol <1µg/dL <1µg/dL 7–25 µg/dL
TSH 1.31 mIU/mL 0.19 mIU/mL 0.3–3.5 mIU/mL
fT4 0.89 ng/dL 0.52 ng/dL 0.8–2.0 ng/dL
LH 9.62 mIU/mL 0.41 mIU/mL 10.4–64.6 mIU/mL
FSH 49.7 mIU/mL 0.59 mIU/mL 26.7–133.4 mIU/mL
PRL 13.1 ng/mL 18.6 ng/mL < 20 ng/mL
Oestradiol < 20 pg/mL < 20 pg/mL 0–30 pg/mL
Figure 2. Gadolinium-enhanced T1-weighted sagittal and 
coronal MRI three months (A, B) and 60 months (C, D) after 
the apoplectic event showed complete resolution of the pituitary 
tumour. Secondary empty sella with left, lateral displacement of 
the pituitary stalk and flattened pituitary gland are seen. Optic 
chiasm is distorted and drawn to the sella
Rycina 2. Badanie MR po podaniu środka kontrastowego 
w czasie T1-zależnym, w przekroju czołowym i strzałkowym po 
trzech miesiącach (A, B) oraz po 60 miesiącach (C, D) od epizodu 
udaru przysadki wykazało regresję gruczolaka. Widoczne wtórnie 
puste siodło tureckie z przemieszczeniem szypuły przysadki 
na stronę lewą. Skrzyżowanie wzrokowe jest przemieszczone 
i pociągane do siodła tureckiego
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either an infarction or haemorrhage. In a case of infarc-
tive PA, no intrasellar haemorrhage is seen in MRI. The 
tumour mass has low signal intensity on T1-weighted 
and T2-weighted MRI and no enhancement is seen 
after gadolinium administration, with the exception 
of peripheral enhancement of the tumour’s capsule in 
acute, subacute and chronic phases of this condition 
[9]. Peripheral enhancement is not typical for infarc-
tive PA and can also be seen in cases of cystic pituitary 
adenomas and craniopharyngiomas [8]. In the pre-
sented case, pathological sellar mass had a dark signal in 
T1-weighted images and rim enhancement was ob-
served, but T2-weighted images suggested intratumour-
al haemorrhage. Furthermore, a massive thickening of 
the sphenoid sinus mucosa was present. This phenom-
enon was first described by Arita et al. [10]. They specu-
lated that thickening of the sphenoid sinus mucosa is 
caused by venous congestion due to a sudden increase 
of intrasellar pressure. Liu and Couldwell reported that 
the presence of sphenoid sinus mucosa thickening fol-
lowing PA might be accompanied by an increased rate 
of cranial nerves deficits at presentation [3]. This finding 
appears to be associated with worse endocrinological 
(hypopituitarism and subsequent long-term hormonal 
replacement therapy) and ophthalmological outcomes. 
[9]. In the reported case, it also seems that visual im-
pairment at presentation and post-apoplectic pituitary 
insufficiency might be related to the thickening of the 
sphenoid sinus mucosa detected in MRI.
The spontaneous regression of hormone secret-
ing pituitary adenomas following PA is a well known 
phenomenon [11–14]. Quoted authors have reported 
“spontaneous recovery” from hormone hypersecretion 
and concomitant endocrine symptomatology. Accord-
ing to Kamiya et al., late recurrences of the primary 
endocrinopathy and tumour regrowth following PA is 
often observed [15].
In cases of non-functioning pituitary tumours 
(which are ordinarily macroadenomas), a spontane-
ous disappearance caused by PA is rarely seen [16, 17]. 
Early adenoma regrowth is often noted, and surgery 
is the recommended treatment modality because tu-
mour growth is usually accompanied by ‘mass effect’ 
and visual field abnormalities [18]. Furthermore, if PA 
results in a secondary empty sella, displacement of 
the optic chiasm into the sella might complicate visual 
outcome [17].
Besides, non-functioning pituitary adenomas 
treated surgically recur more commonly in patients with 
residual tumour [2]. Chen et al. reported a higher rate 
of tumour regrowth in a series of non-functioning pi-
tuitary adenomas following pituitary tumour apoplexy 
compared to non-apoplectic tumours [19]. For now, 
there is no rational explanation for this phenomenon.
In our centre, an immediate surgical intervention 
in a case of haemorrhagic pituitary tumour apoplexy 
is usually recommended. In the reported case of 
a non-functioning pituitary adenoma, both a clinical 
presentation and MRI results were strongly suggestive 
for infarctive PA. Additionally, the patient refused to 
undergo pituitary surgery. Thus we had the opportunity 
to observe a natural history of the pituitary tumour apo-
plexy treated conservatively. Its complete disappearance 
was documented in serial MR images over the course of 
five years of follow-up. In our opinion, clinically evident 
pituitary infarction destroyed the whole tumour, in con-
trast to cases of intratumoural haemorrhage, in which 
only part of the tumour is usually damaged.
It cannot be determined whether conservative or 
more invasive management provides better results in 
such difficult cases. Most authors recommend prompt 
neurosurgical intervention in patients with symptoms 
such as: diminished level of consciousness, prominent 
visual disturbances and neurological deficits [20,21]. 
They argue that immediate debulking surgery leads 
to better neurological and endocrinological outcomes. 
However, in some studies, medical therapy is advocated 
[22]. Ayuk et al. and Sibal et al. reported no significant 
differences in terms of recovery of the pituitary function 
and visual impairment between patients treated con-
servatively and surgically [22, 23]. Gruber et al. found 
no evidence that a surgical approach is characterised by 
a better outcome [24]. A review of the literature by Ni-
shioka et al. showed that pituitary insufficiency usually 
develops following haemorrhagic apoplexy, whereas 
pituitary function is more commonly preserved after 
infarctive apoplexy [12].
Considering the above, hormone replacement fol-
lowing PA is indispensable for nearly 80% of patients. 
There have been no significant differences confirmed 
between surgically and conservatively treated patients 
[9]. With regards to visual outcomes, better results are 
more likely in patients after prompt neurosurgical 
intervention [25]. In the presented case, a conservative 
treatment provided excellent neuro-ophthalmologic 
results, but permanent pituitary insufficiency occurred.
In such a life-threatening case, the appropriate 
treatment is crucial for mortality, morbidity and further 
prognosis. The most important issue is to emergently 
stabilise the patient`s general condition. Pituitary 
function is usually violently compromised. Therefore 
(following endocrine evaluation), the rapid intravenous 
administration of high dose glucocorticosteroids is rec-
ommended [1, 9, 22, 23].
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It should be stated that the incidence of tumour 
recurrence after pituitary tumour apoplexy is not 
known. Randeva et al. observed adenoma regrowth in 
6% of patients following PA surgery [20]. Gruber et al. 
reported later relapse of a pituitary adenoma after an 
apoplectic event in 23% of patients [24]. Therefore, all 
patients after PA require prolonged endocrine and im-
aging follow-up as well as close collaboration between 
neurosurgical and endocrinological teams. In terms of 
frequency of imaging studies, Rajasekaran et al. recom-
mended the implementation of MRI 3-6 months after 
an episode of PA, then once per year for five years and 
every two years thereafter [9].
Conclusion
In the described case, the tumour infarction (infarctive 
PA) destroyed the whole clinically evident pituitary 
tumour, unlike an intratumoural haemorrhage (haem-
orrhagic PA) when only part of the tumour is usually 
damaged. We think that, in selected cases, pituitary 
tumour apoplexy could be treated conservatively. Such 
a treatment may result in resolution of neurological dis-
turbances, although the pituitary insufficiency might be 
permanent. Additionally, the presented case confirms 
that PA may be the first manifestation of pituitary ad-
enoma and highlights an increasing problem in patients 
on anticoagulant therapy.
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